I2BM

I2BM (Innovation to Business in Medicine) is a clinical-stage South Korean biotechnology company specializing in the development of small molecule therapeutics for fibrosis, oncology, and metabolic diseases. Founded in 2020, the company utilizes a proprietary medicinal chemistry platform to identify and optimize novel drug candidates. Its lead program, IBM-101, is a selective ALK5 (TGF-beta receptor type 1) inhibitor currently in Phase 1 clinical trials for the treatment of fibrotic conditions such as non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). I2BM's broader pipeline includes early-stage assets targeting various kinases and metabolic pathways, supported by a leadership team with deep expertise in the Korean pharmaceutical industry. The company aims to bridge the gap between academic research and commercial success through its efficient drug discovery engine.